CervoMed to Present Phase 2b Trial Results
Company Announcements

CervoMed to Present Phase 2b Trial Results

The latest announcement is out from CervoMed ( (CRVO) ).

CervoMed Inc., a clinical-stage company developing treatments for neurologic disorders, will present detailed safety and efficacy results from its RewinD-LB Phase 2b trial at the International Lewy Body Dementia Conference in Amsterdam. The trial focuses on neflamapimod, a potential therapy for dementia with Lewy bodies, with topline results expected in December 2024. This development is highly anticipated given the current lack of approved therapies for this condition, drawing significant interest from the scientific community.

For an in-depth examination of CRVO stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCervoMed to present at International Lewy Body Dementia Conference
TheFlyCervoMed reports last patient last visit in Phase 2b RewinD-LB trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App